BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today announced that CEO Stephen Dilly, M.B.B.S., Ph.D., will present a company overview at the Cowen and Company 37th Annual Health Care Conference on Wednesday, March 8, 2017, at 10:00 a.m. Eastern Time and at the Barclays Capital Global Healthcare Conference on Thursday, March 16, 2017, at 11:15 a.m. Eastern Time.
The live webcasts of the presentations will be accessible on the Events page under the Investor Relations section of the Aimmune website at www.aimmune.com. The replays of the webcasts will be available for at least 30 days following each webcast.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to achieve meaningful levels of protection by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational biologic product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4-17 years of age and is currently being evaluated in Phase 3 clinical trials. For more information, please see www.aimmune.com.